



U.S. Department of Commerce  
Date Filed: 12 November 2007

DOCKET NO. 61169.00040  
(O-2863 CIP)

APPLN. NO. 10/812,292

APPLICANT: Discher et al.

FILING DATE: March 29, 2004

GROUP: 1615

### U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract

### OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, etc.)

1		<i>Arcamone F.</i> , Doxorubicin: Anticancer Antibiotics, Academic Press, New York, 1981.
2		<i>Hobbie R.K. et al.</i> , "Transport through neutral membranes," Intermediate Physics for Medicine and Biology, 3 <sup>rd</sup> ed., AIP Press, New York, 114-124 (1997).
3		<i>Jellinek H.H.G.</i> , "Aspects of Degradation and Stabilization of Polymers," Elsevier, New York, 617-657 (1978).
4		<i>Lasic et al.</i> , "Medical Applications of Liposomes," Elsevier, New York, pp. 1-24 (1998).
5		<i>Li X. et al.</i> , "In Vitro Protein Release and Degradation of Poly-dl-lactide-poly(ethylene glycol) Microspheres with Entrapped Human Serum Albumin: Quantitative Evaluation of the Factors Involved in Protein Release Phases," <i>Pharmaceutical Research</i> , 18(1): 117-124.
6		<i>Pitt C.G.</i> , "Poly(e-caprolactone) and its copolymers," R. Langer and M. Chasin (Eds.), Biodegradable Polymers as Drug Delivery Systems, Marcel Dekker, New York, NY, pp. 71-120 (1990).
7		<i>Piskins et al.</i> , "Novel PDLLA/PEG copolymer micelles as drug carriers," <i>J. Biomaterials Science, Polymer Ed.</i> 7:359-373 (1995).
8		<i>Shah et al.</i> , "Poly-DL-lactic acid: polyethylene glycol block copolymers. The influence of polyethylene glycol on the degradation of poly-DL-lactic acid," <i>Biomaterials Science, Polymer Ed.</i> 5:421-431 (1994).
9		<i>Szleifer et al.</i> , "Curvature Elasticity of Pure and Mixed Surfactant Films," <i>Phys. Rev. Lett.</i> 60(19):1966 (1988).

Examiner Signature:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

The following references are listed on the Information Disclosure Statement, but are not presently available. The copies will follow in a Supplemental Information Disclosure Statement.

*Arcamone F.*, Doxorubicin: Anticancer Antibiotics, Academic Press, New York, 1981.*Jellinek et al.*

*Jellinek H.H.G.*, "Aspects of Degradation and Stabilization of Polymers," Elsevier, New York, 617-657 (1978).

*Pitt C.G.*, "Poly(e-caprolactone) and its copolymers," R. Langer and M. Chasin (Eds.), Biodegradable Polymers as Drug Delivery Systems, Marcel Dekker, New York, NY, pp. 71-120 (1990).

*Piskins et al.*, "Novel PDLLA/PEG copolymer micelles as drug carriers," J. Biomaterials Science, Polymer Ed. 7:359-373 (1995).

*Shah et al.*, "Poly-DL-lactic acid: polyethylene glycol block copolymers. The influence of polyethylene glycol on the degradation of poly-DL-lactic acid," Biomaterials Science, Polymer Ed. 5:421-431 (1994).

*Szleifer et al.*, "Curvature Elasticity of Pure and Mixed Surfactant Films," Phys. Rev. Lett. 60(19):1966 (1988).

*Hobbie R.K. et al.*, "Transport through neutral membranes," Intermediate Physics for Medicine and Biology, 3<sup>rd</sup> ed., AIP Press, New York, 114-124 (1997).

*Lasic D.D. et al.*, "Papahadjopoulos, Medical Applications of Liposomes," Elsevier, Amsterdam, New York, 1-16(1998).